

MPN Driver Genes and the Importance of Molecular Genetic Testing

References

1. Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. *Blood Cancer J*. 2018;8(2):15.; doi: [10.1038/s41408-018-0054-y](https://doi.org/10.1038/s41408-018-0054-y)
2. Mesa R, Jamieson C, Bhatia R, et al. Myeloproliferative neoplasms, version 2.2017, NCCN clinical practice guidelines in oncology. *J Natl Compr Canc Netw*. 2016;14:1572-1611.
3. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. *Am J Hematol*. 2017;92:94-108. doi: 10.1002/ajh.24607.
4. Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. *Blood*. 2017;129:680-692. doi:10.1182/blood-2016-10-695957.
5. Zaidi U, Sufaida G, Rashid M, et al. A distinct molecular mutational profile and its clinical impact in essential thrombocythemia and primary myelofibrosis patients. *BMC Cancer*. 2020;20:205. <https://doi.org/10.1186/s12885-020-6700-3>.
6. Pettit KM, Kandarpa M, Robinson D, et al. Genomic landscape and clinical features of triple-negative myelofibrosis. *Clin Lymphoma Myeloma Leuk*. 2018;18(suppl; abstr MPN-285). doi: 10.1016/j.clml.2018.07.187.
7. Guglielmelli P, Carobbio A, Rumi E. et al. Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. *Blood Cancer J*. 2020;10:21. <https://doi.org/10.1038/s41408-020-0289-2>
8. Asp J, Andréasson B, Hansson U, et al. Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome. *Haematologica*. 2016;101:e129-e132.
9. Grinfeld J, Nangalia J, Baxter J, et al. Classification and personalized prognosis in myeloproliferative neoplasms. *N Engl J Med*. 2018;379:1416-1430. doi: 10.1056/NEJMoa1716614.
10. Guglielmelli P, Lasho TL, Rotunno G, et al. MIPSS70: Mutation-Enhanced International Prognostic Score System for transplantation-age patients with primary myelofibrosis. *J Clin Oncol*. 2018;36:310-318.
11. Bose P, Verstovsek S. Mutational profiling in myelofibrosis: Implications for management. *Int J Haematol*. 2020;111:192-199.
12. Tefferi A, Lasho TL, Guglielmelli P, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. *Blood Adv*. 2016;1:21-30.
13. Tefferi A, Lasho TL, Abdel-Wahab O, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. *Leukemia*. 2010;24:1302-1309.

14. Senín A, Fernández-Rodríguez C, Bellosillo B, et al. Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up. *Ann Hematol.* 2018;97:443-451.
15. Chifotides HT, Masarova L, Alfayez M, et al. Outcome of patients with *IDH1/2*-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. *Blood Adv.* 2020;4:5336-5342.
16. Patel AA, Cahill K, Charnot-Katsikas A, et al. Clinical outcomes of *IDH2*-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. *Br J Haematol.* 2020;190(1):e48-e51. <https://doi.org/10.1111/bjh.16709>.
17. Takata Y, Seki R, Kanajii T, et al. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms. *Kurume Med J.* 2014;60:89-97.
18. Zhang Y, Zhou Y, Wang Y, et al. Thrombosis among 1537 patients with *JAK2*^{V617F}-mutated myeloproliferative neoplasms: Risk factors and development of a predictive model. *Cancer Med.* 2020;9(6):2096-2105. <https://doi.org/10.1002/cam4.2886>.
19. Guy A, Gourdou-Latyszenok V, Le Lay N, et al. Vascular endothelial cell expression of *JAK2*^{V617F} is sufficient to promote a pro-thrombotic state due to increased P-selectin expression. *Hematologica.* 2019;104:70-81.
20. Etheridge SL, Roh ME, Cosgrove ME, et al. JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms. *Proc Natl Acad Sci U S A.* 2014;111:2295-2300.
21. Reeves B, Kim SJ, Song J, et al. Upregulation of tissue factor may contribute to thrombosis in polycythemia vera and essential thrombocythemia. *Blood.* 2018;132 (Supplement 1):2513.
22. Matsuura S, Thompson CR, Belghasem E, et al. Platelet dysfunction and thrombosis in JAK2 V617F-mutated primary myelofibrotic mice. *Arterioscler Thromb Vasc Biol.* 2020;40:e262-e272.
23. IPSET. <https://www.siematologia.it/LG/IPSET%20thrombosi/IPSET%20thrombosi.htm>
24. Regling K, Bagla S, Zaidi AU, et al. *RUNX1* associated familial platelet disorder with myeloid malignancy (FPD-MM) in children: A novel new phenotype with juvenile and chronic myelomonocytic leukemia (JMML/CMML) characteristics. *Blood.* 2018;132 (Supplement 1):5504.